Ki-ras mutations and prognosis in colorectal cancer

European Journal of Cancer

Volumn 34, Issue 4, 1998, Pages 518-521

  Kressner, U ^a,b   Bjorheim J ^a   Westring, S ^a,c   Wahlberg, S S ^a,d   Pahlman L ^a   Glimelius, B ^a,e   Lindmark, G ^a,b   Lindblom, A ^a,b   Borresen Dale A L ^a,c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Department of Genetics ^*  (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Colorectal cancer; Ki ras; Survival time; Tumour differentiation; Tumour stage

Indexed keywords

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENES, RAS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POINT MUTATION; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0032033144     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10111-3     Document Type: Article

References (31)

1. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. New Engl J Med 1997, 336, 980-987.
2. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994,330, 1136-1142.
3. Glimelius B, Isacsson U, Jung B, Påhlman L. Radiotherapy in addition to radical surgery in rectal cancer: evidence for a dose-response effect favoring preoperative treatment. Int J Radiat Oncol Biol Phys 1997, 37, 281-287.
4. Graf W, Westlin JE, Påhlman L, Glimelius B. Adjuvant intraperitoneal 5-flourouracil and intravenous leucovorin after colorectal cancer surgery: a randomized placebo-controlled phase I study. Int J Colored Dis 1992, 9, 35-39.
5. Liver Infusion Meta-analysis Group. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997, 89, 497-505.
6. Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61, 759-767.
7. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987, 327, 298-303.
8. Capella G, Cronauer-Mitra S, Peinado M, Perucho M. Frequency and spectrum of mutations at codon 12 and 13 of the cK-ras gene in human tumors. Environ Health Perspect 1991, 93, 125-131.
9. Fearon E. K-ras gene mutation as a pathogenic and diagnostic marker in human cancer. J Natl Cancer Inst 1993,85, 1978-1981.
10. McCormick F. Signal transduction. How receptor turns ras on. Nature 1993, 63, 15-16.
11. Benhattar J, Losi L, Chaubert P, Givel JC, Costa J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1993, 104, 1044-1048.
12. Finkelstein S, Przygodski R, Pricolo V, et al. Prediction of biologic aggressiveness in colorectal cancer by p53/K-ras-2 topographic genotyping. Molec Diagn 1996, 1, 5-28.
13. Morrin M, Kelly M, Barret N, Delaney P. Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. Gut 1994, 35, 1627-1631.
14. Norheim-Andersen S, Lövig T, Breivik J, et al. K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol 1997,32, 62-69.
15. Bell SM, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993, 104, 57-64.
16. Miyahara M, Saito T, Kaketani K, et al. Clinical significance of ras p21 overexpression for patients with an advanced colorectal cancer. Dis Colon Rectum 1991, 34, 1097-1102.
17. Sun XF, Wingren S, Carstensen JM, et al. Ras p21 expression in relation to DNA ploidy, S-phase fraction and prognosis in colorectal adenocarcinoma. Eur J Cancer 1991, 27A, 1646-1649.
18. Morson B, Sobin L. Histological typing of intestinal tumors. International Histological Classification of Tumours, Vol. 15. Geneva, WHO, 1976.
19. Dukes CE, Bussey HJR. The spread of rectal cancer and its effect on prognosis. Br J Cancer 1958, 12, 309-320.
20. Borresen-Dale AL, Lystad S, Langerod A. Temporal temperature gradient gel electrophoresis (TTGE) compared with denaturing gradient gel electrophoresis (DGGE) and constant dénaturant gel electrophoresis (CDGE) in mutation screening. Bioradiation US/EG Bulletin 2133, 1997.
21. Borresen-Dale AL. In Pfeifer, ed. Constant Denaturant Gel Electrophoresis (CDGE) in Mutation Screening in Technologies for Detection of DNA Damage and Mutation, Vol. 20. New York, Plenum Press, 1996, 267-279.
22. Fischer SG, Lerman LS. DNA fragments differing by single base-pair substitutions are separated in denaturing gradient gels. Corresponding with melting theory. Proc Natl Acad Sei USA 1983,80, 1579-1583.
23. Hovig E, Smith-Sorensen B, Brogger A, Borresen A-L. Constant dénaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection. Mutation Res 1991,262, 63-71.
24. Andreyev J, Norman A, Cunningham D, Dates J, Clarke P. Kiras mutations in 2,667 patients with colorectal cancer; RASCAL collaboration (abstract). Proc ASCO 1997, 16, 257a.
25. Lindmark G, Gerdin B, Påhlman L, Bergström R, Glimelius B. Prognostic predictors in colorectal cancer. Dis Colon Rectum 1994,37, 1219-1227.
26. Elnatan J, Goh HS, Smith DR. C-Ki-ras activation and the biological behaviour of proximal and distal colonie adenocarcinomas. Eur J Cancer 1996, 32A, 491-497.
27. Goh HS, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995, 55, 5217-5221.
28. Jen J, Hougen K, Piandosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N EnglJ Med 1994, 331, 213-221.
29. Martinez JA, Prevot S, Nordlinger B, et al. Overexpression of nm23-Hl and nm23-H2 genes in colorectal carcinomas and loss of nm23-Hl expression in advanced tumour stages. Gut 1995, 37, 712-720.
30. Kressner U, Lindmark G, Gerdin B, Pahlman L, Glimelius B. Immunohistochemical p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res 1996, 16, 951-958.
31. Lindmark G. Nm 23-H1 immunohistochemistry is not useful as a predictor of metastatic potential of colorectal cancer. Br J Cancer 1996, 74, 1413-1418.